The standard chemotherapy for advanced GC includes a combination of fluoropyrimidine and platinum compounds, with human epidermal growth factor receptor 2 (HER2)-targeted trastuzumab, vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ramucirumab, and immune checkpoint inhibitors, nivolumab and pembrolizumab [9]. This evidence concerns the gene ERBB2 and gastric cancer.